Rallybio (RLYB) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
2 Feb, 2026Opening remarks and agenda
The meeting was called to order by the Chairman, welcoming stockholders and outlining virtual participation procedures.
Only stockholders of record as of December 30, 2025, could participate and vote.
Specific resolutions to be voted on
Proposal 1 sought approval for an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1:5 and 1:20, to be determined by the Board.
Proposal 2 allowed for consideration of any other business that may properly come before the meeting or any adjournment.
Corporate governance
Broadridge Financial Services was appointed as Inspector of Elections, with Marlene Aguilar taking the oath.
The record date for voting was set as December 30, 2025, with 42,243,777 shares outstanding.
A quorum was established with 82.81% of voting power represented.
Latest events from Rallybio
- Merger-related proposals and charter changes passed; directors were elected and the auditor ratified.RLYB
AGM 2026 - A $50.0M termination fee drove 9M profit as the Avenzo merger advanced.RLYB
Q3 2026 - Q2 2026 net income soared on a $50M termination fee; Avenzo merger to reshape ownership.RLYB
Q2 2026 - Q1 2026 net loss narrowed, R&D costs fell, and a $50M merger termination fee boosted liquidity.RLYB
Q1 2026 - Merger creates a well-funded oncology biotech advancing four clinical-stage cancer therapies.RLYB
M&A announcement - Net loss improved to $9.0 million in 2025 amid a pending merger, asset sale, and cost reductions.RLYB
Q4 2025 - Merger forms a TCE therapeutics leader with $700M cash and a broad autoimmune disease pipeline.RLYB
M&A announcement - Best-in-class efficacy, improved tolerability, and strong market demand drive $6B opportunity.RLYB
Status Update - Rare disease pipeline advances, with key clinical milestones and new data expected in 2024.RLYB
7th Annual Evercore HealthCONx Conference